Adams Respiratory and Lipocine to develop new products

Under the terms of the agreement, Adams will receive an exclusive, royalty- bearing license from Lipocine to develop and market multiple prescription adult cough products in North America. Lipocine will be responsible for completing the product development work and will be eligible to receive reimbursements and payments in exchange for completing certain pre-defined development milestones.

Adams will be responsible for performing all aspects of clinical development, regulatory submission, manufacture and commercial operations. Financial terms of the deal were not disclosed.

Robert Casale, COO of Adams Respiratory, said: “This collaboration with Lipocine provides Adams with access to an additional proprietary platform technology and fits with our strategy of taking established compounds and adding increased functionality to create patent-protected, value-added products. The products developed through this collaboration could offer doctors a non-narcotic prescribing option to treat cough with an enhanced dosing regimen.”

Dr Mahesh Patel, president and CEO of Lipocine, said: “Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments.”